24/7 Wall St. on MSN18h
AbbVie Just Paid Investors: Here's How Much They ReceivedAbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...
We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...
Insider Monkey on MSN9d
Jim Cramer Says AbbVie Inc. (ABBV) Is A ‘Buy’We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
The stock's fall snapped a two-day winning streak.
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat.com ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
Xilio Therapeutics Inc. is banking $52 million up front from Abbvie Inc., including a $10 million equity investment, plus about $2.1 billion in contingent payments for option-related fees and ...
AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback